Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...
As a consequence of these gene profiling studies ... Of particular note are the gatekeeper residue mutations in BCR–ABL, KIT and platelet-derived growth factor receptor (PDGFR), which lead ...
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback